Claims

1-8 (Cancelled)

9. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a catechin and a pharmaceutically acceptable carrier, diluent, or excipient, the therapeutic amount of the catechin selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.

10. (Original) The composition of claim 9 wherein the therapeutically effective amount of the catechin comprises a dosage in the range of about 10 to 1,000 mg/kg of body weight of the subject.

11. (Original) The composition of claim 10 wherein the therapeutically effective amount of the catechin comprises a dosage in the range of about 10 to 100 mg/kg of body weight of the subject.

12. (Original) The composition of claim 9 wherein the catechin is selected from the group consisting of catechin, epicatechin, gallocatechin gallate, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts of the foregoing catechins, and the pharmaceutically acceptable analogs and derivatives thereof.

13. (Original) The composition of claim 12 comprising a mixture of two or more of the catechins selected from the group consisting of catechin, epicatechin, gallocatechin gallate, epigallocatechin gallate, epigallocatechin, and epicatechin gallate, and pharmaceutically acceptable salts of the foregoing catechins, and the pharmaceutically acceptable analogs and derivatives thereof.

14. (Original) The composition of claim 12 wherein each catechin selected is present in a percentage purity that significantly exceeds a proportion percentage of the catechin presence in a plant, or extract from a plant.

15. (Original) The composition of claim 15 wherein the catechin selected is in substantially pure isolated or synthetic form.

16. (Cancelled)

17. (New) A pharmaceutical composition consisting of a therapeutically effective amount of a catechin and of a pharmaceutically acceptable carrier, diluent, or excipient, the therapeutic amount of the catechin selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.

18. (New) A drug product comprising a container labeled or accompanied by a label indicating that the drug product is for the treatment of amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject, container containing one or more dosage units each comprising a therapeutically effective amount of a catechin and of a pharmaceutically acceptable carrier, diluent, or excipient, the therapeutic amount of the catechin selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in the mammalian subject.

Respectfully submitted,

P16CI-NONCOM2.TRN

PATRICK MICHAEL DWYER
Reg. No. 32,411

PATRICK M. DWYER
PROTEOTECH, INC
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109